Results 31 to 40 of about 940,848 (345)

High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor

Vaccines, 2022
Hepatitis C virus (HCV) infections pose a major public health burden due to high chronicity rates and associated morbidity and mortality. A vaccine protecting against chronic infection is not available but would be important for global control of HCV ...
Anna Offersgaard, Carlos Rene Duarte Hernandez, Anne Finne Pihl, Nandini Prabhakar Venkatesan, Henrik Krarup, Xiangliang Lin, Udo Reichl, Jens Bukh, Yvonne Genzel, Judith Margarete Gottwein   +9 more
doaj   +1 more source

Liver transplantation for viral hepatitis in 2015 [PDF]

, 2016
Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and for patients with liver cell cancer related to liver disease.
Bortoluzzi, Ilaria, Burra, Patrizia, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Nadal, Elena, Russo, FRANCESCO PAOLO, Senzolo, Marco, Zanetto, Alberto   +8 more
core   +1 more source

Seroprevalensi Hepatitis C pada Populasi Perkotaan dan Perdesaan di Indonesia Tahun 2013: Kajian Determinan Sosiodemografi, Lingkungan, Pejamu, dan Komorbiditas (Analisis Lanjut Riskesdas 2013) [PDF]

, 2017
Hepatitis C is an infectious disease caused by RNA virus that is often asymptomatic and can lead into serious complications such as liver cancer. It remains one of major public health issues in several developing countries.
Dany, F. (Frans), Handayani, S. (Sarwo)
core   +1 more source

Risk factors for familial clustering of hepatitis C virus infection in a Chinese Han population: a cross-sectional study

BMC Public Health, 2018
Background Hepatitis C is a curable disease, but reinfection from household contact may occur in patients who have achieved sustained viral response (SVR).
Bi-fen Luo, Hui-ying Rao, Ying-hui Gao, Lai Wei   +3 more
doaj   +1 more source

Incidence, prevalence, and clinical course of hepatitis C following liver transplantation [PDF]

, 1992
Hepatitis C virus (HCV) is the agent responsible for posttransfusion hepatitis. The incidence, timing, and clinical course of HCV positive hepatitis in liver transplant recipients are unknown.
A.Jake Demetris, Aach, Alter, Barcena, Barrera, Brillanti, Choo, Colombo, David H. Van Thiel, Esteban, Esteban, Feinman, Grandele, Gray, Gunjan Shah, Hernandez, Jessica H. Lewis, Judith S. Gavaler, Kaplan, Knodell, Kuo, Kühnl, Mattsson, McFarlane, McHutchison, Noel, Poel, Read, Read, Rumi, Saturo Todo, Simonetti, Stevens, Thomas E. Starzl, Trainer, Weiner   +35 more
core   +1 more source

MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development

Journal of Experimental & Clinical Cancer Research, 2018
Background Identification of novel MDM2 or p53 binding proteins may reveal undefined oncogenes, tumor suppressors, signaling pathways and possible treatment targets.
Xingwang Xie, Xueyan Wang, Weijia Liao, Ran Fei, Nan Wu, Xu Cong, Qian Chen, Lai Wei, Yu Wang, Hongsong Chen   +9 more
doaj   +1 more source

Hepatitis C and hepatic steatosis [PDF]

QJM, 2010
Hepatic steatosis is commonly seen in patients with chronic hepatitis C infection, and the two together have a greater association than by chance alone. Hepatitis C virus is closely associated with lipid metabolism throughout its lifecycle. Hepatic steatosis is more common in genotype 3 infection, due to direct viral effects including through ...
Simon D. Taylor-Robinson, J.H. Patel, Jeremy F. L. Cobbold, Howard C. Thomas   +3 more
openaire   +3 more sources

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]

, 2019
The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G, Cibu, Bianca A, Ciulei, George, Coste, Sorina C, Cozma, Angela, Mureșan, Flaviu, Negrean, Vasile, Orasan, Olga H, Ovidiu, Fabian, Pfingstgraf, Iulia O, Popovici, Ionela E, Tarmure, Simina F, Taut, Adela V. S   +12 more
core   +3 more sources

Neutralisation resistance of SARS-CoV-2 spike-variants is primarily mediated by synergistic receptor binding domain substitutions

Emerging Microbes and Infections
The evolution of SARS-CoV-2 has led to the emergence of numerous variants of concern (VOCs), marked by changes in the viral spike glycoprotein, the primary target for neutralising antibody (nAb) responses. Emerging VOCs, particularly omicron sub-lineages,
Long V. Pham, Alexander P. Underwood, Alekxander Binderup, Ulrik Fahnøe, Carlota Fernandez-Antunez, Blanca Lopez-Mendez, Line Abildgaard Ryberg, Andrea Galli, Christina Sølund, Nina Weis, Santseharay Ramirez, Jens Bukh   +11 more
doaj   +1 more source

Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas^® HBV Test for Use on the Cobas^® 4800 System

Microorganisms, 2021
(1) Background: Sensitive and accurate nucleic acid amplification technologies are now recommended for hepatitis B virus (HBV) DNA detection and quantification in clinical practice to diagnose and monitor hepatitis B infection.
Valérie Ortonne, Mélanie Wlassow, Magali Bouvier-Alias, Giovana Melica, Jean-Dominique Poveda, Syria Laperche, Jean-Michel Pawlotsky, Stephane Chevaliez   +7 more
doaj   +1 more source